Valeant Pharma (VRX) to Make Wilson Disease Charitable Contribution
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/16/2024
- Stocks close lower as Middle East tensions, Treasury yields weigh
- Apple’s iPhone shipments dip 10% in Q1 as Samsung reclaims the top spot
- Tesla (TSLA) to cut over 10% global staff - Electrek
- Aluminum, Nickel, Copper: LME ban on Russian metal creates buying opportunity?
- Informatica (INFA) jumps as Salesforce (CRM) reportedly eyes new mega takeover
- Trump Media & Technology Group (DJT) Files S-1
- Tesla (TSLA) Senior VP Drew Baglino Is Said To Leave The Company - Bloomberg
- General Motors (GM) Said to be Moving Detroit HQ to Dan Gilbert's Hudson Tower - Bloomberg
- The Israeli Air Force Has Completed Its Preparation For An Imminent Attack Against Iran - Reuters
- Biohaven Pharma (BHVN) presents update on degrader platform and summary of progress to date in Phase 1 single ascending dose study for BHV-1300
- After-hours movers: Tesla, Gildan Activewear, Macatawa Bank, and more
- Midday movers: Goldman Sachs and Meta Platforms rise; Apple and Tesla fall
- Nike, Alpine Immune Sciences rise premarket; CarMax, Robinhood and Regeneron fall
- After-hours movers: Alpine Immune Sciences, Costco, and more
- Midday movers: Delta, Taiwan Semiconductor rise; Hexcel falls
Valeant Pharmaceuticals Announces Relaunch Of Generic Ofloxacin Otic Solution
August 8, 2016 5:00 PM EDTLAVAL, Quebec, Aug. 8, 2016 /PRNewswire/ --Â Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced the relaunch of its generic ofloxacin otic solution to treat bacterial ear infections. The product was temporarily discontinued in April 2015 due to an issue concerning the active pharmaceutical ingredient supplier, which has been resolved.
Ofloxacin otic is a quinolone antibiotic solution used to treat outer ear infections in adults and children, chronic middle ear infections in adults and children with perforated eardrums, and acute middle ear infections in children with ear tubes. The... More
Valeant Pharmaceuticals Announces Significant Support For Education And Research Regarding Wilson Disease
August 8, 2016 5:00 PM EDTLAVAL, Quebec, Aug. 8, 2016 /PRNewswire/ --Â Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced its commitment to improving the lives of Wilson disease patients around the world.
Valeant has agreed to provide $100,000 to fund enhanced patient awareness and research into this debilitating disease. This charitable contribution will be used to further the ongoing mission of the Wilson Disease Association (WDA) to facilitate and promote the identification, education, treatment and support of patients and other individuals affected by the disease. In addition to this contribution, Valeant has... More
